A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
← catalyst calendarNCT07522073 · readout in 758 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →. With Qiagen Manchester Ltd.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
588estimated
Sites
219
Countries
Australia, Austria, Belgium +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-09 | actual | When the study began enrolling |
| Primary completion | 2028-09-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumors
Interventions
- Drug: INCB161734
- Drug: Placebo
- Drug: Investigator's choice of chemotherapy — also filed as mFOLFIRINOX, GemNabP
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to approximately 3 years
Progression-free survival (PFS) by BICR
measured Up to approximately 2 years
Objective Response by BICR
measured Up to approximately 2 years
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed